Arimidex

(Anastrozole)

ApprovedSmall molecule

Anastrozole is used to treat hormone receptor-positive breast cancer in postmenopausal women by lowering estrogen levels in the body, which helps slow or stop the growth of cancer cells that depend on estrogen.[2] Arimidex is currently approved and in use across 24 indications[4].[1]

Arimidex is one of 335 small molecule programs targeting Klinefelter's syndrome. It is currently in Approved.

Indications

231

Total Trials

Active Trials

334

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Klinefelter's SyndromeApproved

Breast DiseaseApproved

HypogonadismApproved

Estrogen-Receptor Positive Breast CancerActive, not recruiting

Prader-Willi SyndromeActive, not recruiting

Female Breast CarcinomaActive, not recruiting

ArthralgiaActive, not recruiting

Breast NeoplasmApproved

Breast Ductal Carcinoma in SituApproved

Invasive Breast CarcinomaActive, not recruiting

Klinefelter's SyndromeApproved

Approved

Breast DiseaseApproved

Approved

HypogonadismApproved

Approved

Estrogen-Receptor Positive Breast CancerPreclinical

Active, not recruiting

Prader-Willi SyndromePreclinical

Active, not recruiting

Female Breast CarcinomaApproved

Active, not recruiting

ArthralgiaPreclinical

Active, not recruiting

Breast NeoplasmApproved

Approved

Breast Ductal Carcinoma in SituApproved

Approved

Invasive Breast CarcinomaPreclinical

Active, not recruiting

Showing 10 of 24 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Arimidex

IIstituto Clinico Humanitas

Lexiscan

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Non-Small Cell Lung Cancer

NCT02779751

Phase 1Active, not recruiting

Breast Cancer

NCT02057133

Phase 3Active, not recruiting

Breast Cancer

NCT02246621

Phase 2Recruiting

Breast Cancer

NCT04553770

Q1 2027

Phase 3Active, not recruiting

Breast Ductal Carcinoma in Situ

NCT01272037

Phase 3Active, not recruiting

Breast Cancer

NCT04906395

Clinical

Trials by Indication[1]

Breast Cancer122 trials

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Completed·IiOMEDICO AG·Phase 2·NCT02894398·388 enrolled

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00066573·7,576 enrolled

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00005908·30 enrolled

Show 119 more trials

Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00555477·69 enrolled

Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients

Completed·OOttawa Hospital Research Institute·Phase 2·NCT01972984·20 enrolled

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Terminated·SSWOG Cancer Research Network·Phase 3·NCT02137837·37 enrolled

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

Completed·SSWOG Cancer Research Network·Phase 3·NCT00075764·695 enrolled

Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer

Completed·MMaastricht University Medical Center·Phase 3·NCT00301457·1,914 enrolled

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Completed·IInstitut Claudius Regaud·Phase 4·NCT01553903·29 enrolled

Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00244959·54 enrolled

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 3·NCT02097459·600 enrolled

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT02441946·224 enrolled

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed·PPalleos Healthcare GmbH·Phase 2·NCT03272477·257 enrolled

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03099174·133 enrolled

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT03554044·20 enrolled

Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer

Completed·IInstituto Nacional de Cancerologia de Mexico·N/A·NCT00437853·30 enrolled

Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer

Not yet recruiting·RRegion Örebro County·Phase 3·NCT06223698·3,832 enrolled

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

Terminated·WWashington University School of Medicine·Phase 2·NCT01368263·8 enrolled

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00143390·298 enrolled

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Completed·MMedical College of Wisconsin·Phase 2·NCT03219476·37 enrolled

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

Terminated·SStanford University·Phase 2·NCT00481845·1 enrolled

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

Terminated·MMayo Clinic·Phase 2·NCT00573755·4 enrolled

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00057941·148 enrolled

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT02057133·198 enrolled

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Recruiting·FFudan University·Phase 3·NCT05891093·766 enrolled

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT01597193·101 enrolled

3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00300508·856 enrolled

ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00286117·448 enrolled

Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00354640·11 enrolled

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Completed·UUniversity of Washington·N/A·NCT01153672·8 enrolled

Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00357110·13 enrolled

Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00405938·79 enrolled

Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer

Suspended·TThe Netherlands Cancer Institute·Phase 2·NCT00738777·250 enrolled

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 2·NCT03555877·56 enrolled

The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer

Unknown status·—·Phase 2·NCT02072512·180 enrolled

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04256941·4 enrolled

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT00128843·103 enrolled

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Recruiting·WWashington University School of Medicine·Phase 2·NCT05837455·81 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Completed·HHackensack Meridian Health·Phase 2·NCT00004906

Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

Completed·CCentre Oscar Lambret·Phase 3·NCT00893061·44 enrolled

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

Unknown status·MMidwestern Regional Medical Center·Phase 2·NCT02689921·7 enrolled

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Completed·EETOP IBCSG Partners Foundation·Phase 2·NCT05896566·231 enrolled

Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

Completed· AstraZeneca logo

AstraZeneca··NCT00638391·1,600 enrolled

S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT00217659

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

Recruiting· Novartis logo

Novartis··NCT06905301·240 enrolled

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00077025·174 enrolled

Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00588003·45 enrolled

Pre-Surgical Intervention for Targeted Therapies for Breast Cancer

Completed·—·N/A·NCT01004744·10 enrolled

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01344031·31 enrolled

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00248170·4,172 enrolled

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Completed·HHackensack Meridian Health·Phase 2·NCT00004900

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Unknown status·RRuijin Hospital·Phase 2·NCT04236310·37 enrolled

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT04258163·760 enrolled

A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00274469·205 enrolled

Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients

Unknown status·CChinese Academy of Medical Sciences··NCT02765373·500 enrolled

A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease

Terminated·—·Phase 3·NCT02730091·98 enrolled

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Completed· Roche logo

Roche·Phase 2·NCT04436744·221 enrolled

Breast Cancer Tumor Care Observational Programme

Completed· AstraZeneca logo

AstraZeneca··NCT00660244·150 enrolled

Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole

Completed·HHamilton Health Sciences Corporation··NCT00421447·58 enrolled

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

Terminated·JJapan Breast Cancer Research Network·Phase 2·NCT00437359·240 enrolled

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Completed·JJoyce Marie Slingerland, MD·Phase 1/2·NCT01216176·71 enrolled

Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00066378·71 enrolled

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Unknown status·TTechnical University of Munich·Phase 2·NCT00398489·94 enrolled

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Terminated·UUNICANCER·Phase 3·NCT00053911

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00082277·237 enrolled

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Recruiting·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT04985266·1,100 enrolled

Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT00049062

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Withdrawn·FFred Hutchinson Cancer Center·Phase 4·NCT03238703

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Unknown status·GGruppo Italiano Mammella (GIM)·Phase 3·NCT00688194·396 enrolled

Faslodex Advanced Breast Cancer Local Chinese Study

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00327769·234 enrolled

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT03822468·376 enrolled

Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00081510·110 enrolled

Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer

Terminated·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 2·NCT01262274·57 enrolled

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Terminated· Sanofi logo

Sanofi·Phase 2·NCT04059484·367 enrolled

Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00217399·35 enrolled

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04075604·23 enrolled

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00728949·93 enrolled

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Active, not recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolled

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02291913·48 enrolled

Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.

Terminated·AARCAGY/ GINECO GROUP·Phase 2·NCT02585388·120 enrolled

A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00544986

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00265759·622 enrolled

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Completed·UUniversity of Washington·N/A·NCT01720602·15 enrolled

Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer

Completed·IInstitut Bergonié·Phase 2·NCT00871858·120 enrolled

ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00291759·3,858 enrolled

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT05514054·8,000 enrolled

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Completed·AArvinas Inc.·Phase 2·NCT05549505·152 enrolled

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01776008·16 enrolled

Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer

Completed·QQueen Mary University of London·Phase 3·NCT00078832·3,864 enrolled

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

Terminated·PPalleos Healthcare GmbH·Phase 4·NCT03220178·532 enrolled

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Completed·—·Phase 2·NCT02648477·30 enrolled

Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer

Unknown status·IInstituto Jalisciense de Cancerologia··NCT04389424·300 enrolled

Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients

Completed·UUniversity of Michigan Rogel Cancer Center··NCT01814397·50 enrolled

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT04553770·88 enrolled

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Unknown status·NNational Cancer Centre, Singapore·Phase 2·NCT00687648·70 enrolled

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Unknown status·GGruppo Italiano Mammella (GIM)·Phase 3·NCT00541086·3,697 enrolled

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

Unknown status·FFudan University·Phase 3·NCT00902954·540 enrolled

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

Completed·MMayo Clinic··NCT00719966·109 enrolled

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT01953588·1,473 enrolled

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Completed·JJapan Breast Cancer Research Group·Phase 2·NCT01989780·160 enrolled

Breast Cancer Treatment Based on Organ-like Culture

Unknown status·XXijing Hospital··NCT03925233·300 enrolled

Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer

Completed· AstraZeneca logo

AstraZeneca··NCT00562458·200 enrolled

A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

Unknown status·IInstituto Nacional de Cancer, Brazil·Phase 2·NCT03024580·20 enrolled

Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer

Terminated·LLegacy Health System·Phase 2·NCT00303615·5 enrolled

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

Unknown status·—··NCT05800197·300 enrolled

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

Completed·SStanford University·Phase 2·NCT00186121·35 enrolled

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03874325·17 enrolled

Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer

Terminated· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT04113863·76 enrolled

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Terminated·UUniversity of Arizona·Phase 2·NCT01394211·2 enrolled

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT02246621·493 enrolled

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT02278120·672 enrolled

Second Line Breast Cancer Trial

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00635713·588 enrolled

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT01151215·482 enrolled

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Terminated·GGeorgetown University·Phase 2·NCT00661531·11 enrolled

Arthralgia During Anastrozole Therapy for Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00323479·114 enrolled

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

Completed·MMayo Clinic·Phase 2·NCT04294225·161 enrolled

Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

Completed·UUNICANCER·Phase 2·NCT00629616·116 enrolled

Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Active, not recruiting·TTolmar Inc.·Phase 3·NCT04906395·250 enrolled

Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer OVELIA Study

Enrolling by invitation·TTolmar Inc.·Phase 3·NCT05645536·250 enrolled

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Active, not recruiting·SSWOG Cancer Research Network·Phase 3·NCT01674140·1,939 enrolled

The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients With Breast Cancer

Completed·CCity of Hope Medical Center··NCT00681928·72 enrolled

Phase II, Open-Labeled, Single-Armed Combination Treatment With Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer

Recruiting·UUniversity of California, Irvine·Phase 2·NCT05524584·20 enrolled

Testosterone4 trials

Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading

Withdrawn·MMassachusetts General Hospital·Phase 1·NCT01763541

Testosterone Regulation of the Natriuretic Peptide System

Withdrawn·MMassachusetts General Hospital·N/A·NCT02269072

The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans

Not yet recruiting·UUniversity of British Columbia·N/A·NCT07212712·50 enrolled

Show 1 more trial

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

Completed·NNational Institute on Aging (NIA)·Phase 2·NCT00104572·44 enrolled

Ductal Carcinoma in Situ3 trials

Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women

Completed·RRita Sanghvi, Mehta·Phase 2·NCT00256217·42 enrolled

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ

Completed·QQueen Mary University of London·Phase 3·NCT00072462·2,980 enrolled

Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy

Completed·NNSABP Foundation Inc·Phase 3·NCT00053898·3,104 enrolled

Fed3 trials

Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed Conditions

Completed·—·Phase 1·NCT01155960·36 enrolled

Anastrozole 1 mg Tablets Under Fed Conditions

Completed· Teva logo

Teva·Phase 1·NCT01183390·22 enrolled

Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions

Completed·RRoxane Laboratories·N/A·NCT01155089·32 enrolled

Non-Small Cell Lung Cancer2 trials

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT02779751·100 enrolled

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Terminated·UUniversity of Pittsburgh·Phase 2·NCT00932152·3 enrolled

52 more indications

MPA2 trials

Impact of Estradiol Addback

Completed·MMayo Clinic·Phase 1·NCT01862835·43 enrolled

Impact of Endogenous E2 on SSI and GH Rebound

Completed·MMayo Clinic·Phase 1·NCT02026973·62 enrolled

Fasting Conditions2 trials

Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions

Completed·—·Phase 1·NCT01155947·36 enrolled

Anastrozole 1 mg Tablets Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT01182181·22 enrolled

Gynecomastia2 trials

Gynecomastia Extension Study

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00637182

Open Label Arimidex in Gynecomastia

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00241436·35 enrolled

Steroid2 trials

Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors

Completed·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT00253422·698 enrolled

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00944918·25 enrolled

Metabolic Syndrome2 trials

Insulin Sensitivity in Men With the Metabolic Syndrome

Suspended·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00433173·72 enrolled

Testosterone Effects on Men With the Metabolic Syndrome

Withdrawn·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00382057·72 enrolled

Endocrine Therapy2 trials

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

Unknown status·FFirst Hospital of China Medical University··NCT04666805·1,354 enrolled

To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy

Completed·FFondazione Sandro Pitigliani·Phase 2·NCT02549430·115 enrolled

Growth2 trials

Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

Completed·SStanford University·Phase 4·NCT02137538·79 enrolled

Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

Completed· EMD Serono logo

EMD Serono·Phase 2·NCT00213148·271 enrolled

Bone Density1 trial

ATAC - Bone Density Sub-Protocol

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00784940·308 enrolled

Pulmonary Hypertension1 trial

Pulmonary Hypertension and Anastrozole Trial

Completed·UUniversity of Pennsylvania·Phase 2·NCT03229499·84 enrolled

Postmenopausal Women1 trial

Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

Terminated·UUniversity of Maryland, Baltimore·Phase 2·NCT01234532·5 enrolled

Bone Metastasis1 trial

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Completed·EEmory University·Phase 2·NCT03691493·36 enrolled

Adjuvant1 trial

Secondary Adjuvant Long Term Study With Arimidex

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00295620·3,484 enrolled

Klinefelter Syndrome1 trial

Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome

Recruiting·GGeorgios Papadakis·Phase 3·NCT05586802·150 enrolled

Pulmonary Arterial Hypertension1 trial

Anastrozole in Patients With Pulmonary Arterial Hypertension

Completed·UUniversity of Pennsylvania·Phase 2·NCT01545336·18 enrolled

Phase II1 trial

Phase II Study of Everolimus Beyond Progression

Terminated·EEmory University·Phase 2·NCT02269670·3 enrolled

Treatment1 trial

SMMART Adaptive Clinical Treatment (ACT) Trial

Withdrawn·OOHSU Knight Cancer Institute·Phase 1·NCT05238831

Breast Carcinoma1 trial

Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00287534·1,059 enrolled

Combination Therapy1 trial

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00256698·514 enrolled

Advanced Solid Cancer1 trial

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02093351·79 enrolled

Overweight1 trial

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

Completed·UUniversity of Maryland, Baltimore·N/A·NCT02095184·42 enrolled

Quality of Life1 trial

ATAC - Quality of Life Sub-Protocol

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00784680·308 enrolled

Observational Study1 trial

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Unknown status·—··NCT04852081·1,000 enrolled

Elderly1 trial

Anastrozole Administration in Elderly Hypogonadal Men

Completed·MMassachusetts General Hospital·Phase 2·NCT00136695·88 enrolled

Hormone Therapy1 trial

Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy

Completed·FFederal University of São Paulo·N/A·NCT01016665·71 enrolled

Progesterone Receptor Positive1 trial

Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole

Unknown status·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT00077168·2,000 enrolled

TED1 trial

Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions

Completed·RRoxane Laboratories·N/A·NCT01155102·31 enrolled

Double-blind1 trial

Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers

Completed·MMeditrina Pharmaceuticals·Phase 2·NCT00467493·64 enrolled

Pediatrics1 trial

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00094328·14 enrolled

Hormone Receptor Positive1 trial

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01197170·277 enrolled

Drug Repurposing1 trial

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

Completed·—··NCT05635357·16,989 enrolled

Age1 trial

Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.

Completed·PParc de Salut Mar·Phase 1·NCT04757532·9 enrolled

Breast1 trial

Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics

Completed·RRoswell Park Cancer Institute·N/A·NCT00612560·28 enrolled

Prader-Willi syndrome1 trial

Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome

Unknown status·AAssistance Publique - Hôpitaux de Paris·N/A·NCT01520467·27 enrolled

Endometrial Carcinoma1 trial

Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)

Unknown status·CCentre Leon Berard·Phase 1/2·NCT02730923·72 enrolled

Tics1 trial

ATAC - Pharmacokinetics (PK) Sub-Protocol

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00784862·9,358 enrolled

Function1 trial

Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function

Completed·—·Phase 2·NCT03933618·24 enrolled

Sexual Dysfunction1 trial

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

Completed·—·Phase 2·NCT00179517·40 enrolled

Endometrial1 trial

ATAC - Endometrial Sub-Protocol

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00814125·285 enrolled

Liver1 trial

Liver Safety Under Upfront Arimidex vs Tamoxifen

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00537771·384 enrolled

Male Infertility1 trial

Aromatase Inhibitors in the Treatment of Male Infertility

Terminated·UUniversity of Utah·Phase 3·NCT00440180·20 enrolled

Anatomic Stage II Breast Cancer AJCC v81 trial

A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS Less Than or Equal to 25 (RxFINE-Low)

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT07391774·1,978 enrolled

Low-grade Serous Ovarian Cancer1 trial

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Recruiting·VVerastem, Inc.·Phase 3·NCT06072781·270 enrolled

Advanced Breast Cancer1 trial

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06380751·788 enrolled

Breast Ductal Carcinoma in Situ1 trial

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT01272037·5,018 enrolled

HER2-positive Breast Cancer1 trial

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Active, not recruiting·AAlliance Foundation Trials, LLC.·Phase 3·NCT02947685·518 enrolled

Hypogonadism, Hypogonadotropic1 trial

Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

Completed·BBaylor College of Medicine·Approved·NCT03490513·121 enrolled

Metastatic Breast Cancer1 trial

A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study

Active, not recruiting· Novartis logo

Novartis·Approved·NCT05161195·134 enrolled

Early Breast Cancer1 trial

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05774951·4,300 enrolled

Advanced Breast Carcinoma1 trial

MC1633 Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy

Completed·MMayo Clinic·Phase 2·NCT03179904·17 enrolled

Breast Neoplasms1 trial

A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT07174336·800 enrolled

ER Positive Breast Cancer1 trial

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT05512364·220 enrolled

Unspecified8 trials

Bay98-7196, Dose Finding / POC Study

Completed· Bayer logo

Bayer·Phase 2·NCT02203331·319 enrolled

Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC

Withdrawn·FFudan University·Phase 2·NCT02140437

Patient's Anastrozole Compliance to Therapy Programme

Terminated· AstraZeneca logo

AstraZeneca··NCT00555867·4,923 enrolled

Show 5 more trials

ITT4 Intratesticular Hormonal Milieu in Man (ITT4)

Completed·UUniversity of Washington·Phase 1/2·NCT01215292·46 enrolled

Arimidex Therapy Compliance Electronic Monitoring System

Completed· AstraZeneca logo

AstraZeneca··NCT00936442·104 enrolled

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00295646·1,803 enrolled

Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting·PProf. Wolfgang Janni·Phase 3·NCT02344472·271 enrolled

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Terminated·SSpanish Breast Cancer Research Group·Phase 3·NCT00543127·870 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 27, 1995

ARIMIDEX

NDA NDA020541

Dec 27, 1995

ARIMIDEX

NDA NDA020541

Sep 19, 1997

ARIMIDEX

NDA NDA020541

Feb 6, 1998

ARIMIDEX

NDA NDA020541

Aug 13, 1998

ARIMIDEX

NDA NDA020541

Sep 1, 2000

ARIMIDEX

NDA NDA020541

Aug 2, 2001

ARIMIDEX

NDA NDA020541

Sep 10, 2001

ARIMIDEX

NDA NDA020541

Sep 5, 2002

ARIMIDEX

NDA NDA020541

Oct 7, 2002

ARIMIDEX

NDA NDA020541

Aug 30, 2004

ARIMIDEX

NDA NDA020541

Sep 16, 2005

ARIMIDEX

NDA NDA020541

May 10, 2006

ARIMIDEX

NDA NDA020541

Dec 10, 2008

ARIMIDEX

NDA NDA020541

Dec 10, 2008

ARIMIDEX

NDA NDA020541

Dec 10, 2008

ARIMIDEX

NDA NDA020541

Apr 30, 2009

ARIMIDEX

NDA NDA020541

Apr 30, 2009

ARIMIDEX

NDA NDA020541

Apr 18, 2011

ARIMIDEX

NDA NDA020541

May 1, 2013

ARIMIDEX

NDA NDA020541

May 2, 2014

ARIMIDEX

NDA NDA020541

Dec 13, 2018

ARIMIDEX

NDA NDA020541

Dec 16, 2024

ARIMIDEX

NDA NDA020541

Sources

References

[1]
ClinicalTrials.gov — 231 trial records for Anastrozole. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Arimidex drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Anastrozole compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Anastrozole. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020541). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Istituto Clinico Humanitas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cytochrome P450 19a1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: IIstituto Clinico Humanitas

Arimidex

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Breast Cancer122 trials

Testosterone4 trials

Ductal Carcinoma in Situ3 trials

Fed3 trials

Non-Small Cell Lung Cancer2 trials

MPA2 trials

Fasting Conditions2 trials

Gynecomastia2 trials

Steroid2 trials

Metabolic Syndrome2 trials

Endocrine Therapy2 trials

Growth2 trials

Bone Density1 trial

Pulmonary Hypertension1 trial

Postmenopausal Women1 trial

Bone Metastasis1 trial

Adjuvant1 trial

Klinefelter Syndrome1 trial

Pulmonary Arterial Hypertension1 trial

Phase II1 trial

Treatment1 trial

Breast Carcinoma1 trial

Combination Therapy1 trial

Advanced Solid Cancer1 trial

Overweight1 trial

Quality of Life1 trial

Observational Study1 trial

Elderly1 trial

Hormone Therapy1 trial

Progesterone Receptor Positive1 trial

TED1 trial

Double-blind1 trial

Pediatrics1 trial

Hormone Receptor Positive1 trial

Drug Repurposing1 trial

Age1 trial

Breast1 trial

Prader-Willi syndrome1 trial

Endometrial Carcinoma1 trial

Tics1 trial

Function1 trial

Sexual Dysfunction1 trial

Endometrial1 trial

Liver1 trial

Male Infertility1 trial

Anatomic Stage II Breast Cancer AJCC v81 trial

Low-grade Serous Ovarian Cancer1 trial

Advanced Breast Cancer1 trial

Breast Ductal Carcinoma in Situ1 trial

HER2-positive Breast Cancer1 trial

Hypogonadism, Hypogonadotropic1 trial

Metastatic Breast Cancer1 trial

Early Breast Cancer1 trial

Advanced Breast Carcinoma1 trial

Breast Neoplasms1 trial

ER Positive Breast Cancer1 trial

Unspecified8 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News